AAADV Workshop
  • AAADV WORKSHOP
    • About the Workshop
  • Registration
  • Agenda
  • Scholarships
  • CME
  • VENUE
  • Contact
  • Past Events
    • 2019 AAADV Workshop
      • 2019 Speakers
      • 2019 Event Schedules & Agenda
        • 2019 AAADV WORKSHOP SCHEDULE & AGENDA
        • Schedule for AAADV Pre-Workshop for Patient Advocates
        • Schedule for FDA-Duke Global Pre-Workshop
      • Pre- and Post-Workshop Events
        • Global Regulatory Pre-Workshop
        • Pre-Workshop for Patient Advocates
        • Satellite Session
      • 2019 Program Committee
      • 2019 AAADV WORKSHOP SCHEDULE & AGENDA
    • 2018 AAADV Workshop
    • 2017 AAADV Workshop
    • 2016 AAADV Workshop
  • News Feeds
    • 2019 AAADV DOWNLOADS
    • Gallery
    • Publication
    • Events
    • News
  • Program Committee

2017 AAADV Schedule

Published by aaadv workshop on May 1, 2017May 1, 2017

Wednesday May 3, 2017
Thursday May 4, 2017
Friday May 5, 2017
Wednesday May 3, 2017

08:00 AM
Introductions and Overview
H. Kim Lyerly, M.D.
AAADV Chair

08:15 AM
Plenary Session I
A Systems Biology Approach to Cancer Drug Discovery and Development: Master Regulators as Drug Targets
Moderator :
Gregory Reaman, M.D.; U.S. Food and Drug Administration
A Systems Biology Approach to Cancer Drug Discovery and Development
Speaker :
Andrea Califano, Ph.D.; Columbia University
Systems Pharmacology
Speaker :
Peter Sorger, Ph.D.; Harvard University
Panel Discussion

10:15 AM
Break

10:45 AM
Regulatory Sciences I (learners choose one)
Biomarkers in Cancer Clinical Trials : Eligibility, Endpoints and Surrogates; Moderator: Thomas Fleming, Ph.D., University of Washington
Panelists :
Thomas Fleming, Ph.D.; University of Washington
Lisa McShane, Ph.D.; National Cancer Institute
Mary Redman, Ph.D.; Fred Hutchinson Cancer Research Center
Rajeshwari Sridhara, Ph.D.; U.S. Food and Drug Administration
Expanding Role of Data Science and Bioinformatics in Drug Discovery and Development
Moderator :
Ari Caroline, Ph.D.; Memorial Sloan-Kettering Cancer Center
Panelists : 

Sean Khozin, M.D., M.P.H.; U.S. Food and Drug Administration
Howard Fingert, M.D.; Takeda Oncology
Shahram Ebadollahi, Ph.D., M.B.A.; IBM Watson Health
Martin Murphy, D.Med.Sc., Ph.D., FASCO; Project Data Sphere, CEO Roundtable on Cancer

12:45 PM
Lunch

01:45 PM
Keynote Session
White House Cancer Moonshot: Realities for Cancer Drug Development Through Implementation of NCI and FDA Moonshot Initiatives
Speakers :
Richard Pazdur, M.D.; U.S. Food and Drug Administration
Jeffrey Abrams, M.D.; National Cancer Institute
Panel Discussion: Implementation of the Oncology Center of Excellence; Moderator: Richard Pazdur, M.D., U.S. Food and Drug Adminstration

03:15 PM
Break

03:45 PM
In-Depth Discussion Groups I (learners choose one)
Incorporating the Role of Radiotherapy in Clinical Trials of New Drugs
Moderator :
Amanda Walker, M.D.; U.S. Food and Drug Administration
Panelists : 

Silvia Formenti, M.D.; Weill Cornell Medicine
David Raben, M.D.; University of Colorado
Ozlem Ataman, M.D., Ph.D.; Eisai Pharmaceuticals
Ricky Sharma, M.D., Ph.D.; University College London
Adaptive Clinical Trial Designs: What Works
Moderator :
Brian P. Hobbs, Ph.D.; MD Anderson Cancer Center
Enrolling Adolscents in Disease- and Target-Appropriate Adult Oncology Clinical Trials
Moderator :
Meredith Chuk, M.D.; U.S. Food and Drug Administration
Panelists : 

Ruby Leong, Pharm.D.; U.S. Food and Drug Administration
Micah Hester, Ph.D.; University of Arkansas for Medical Sciences
Lara Davis, M.D.; Oregon Health and Sciences University
Nita Seibel, M.D.; National Cancer Institute
Vicki Traller, Patient Advocate; 4Nathalie
Special Considerations for Cancer Drug Development in Older Adults
Moderators : 

Bindu Kanapuru, M.D.; U.S. Food and Drug Administration
Harpreet Singh, M.D.; U.S. Food and Drug Administration
Panelists –

Stuart Lichtman, M.D.; Memorial Sloan-Kettering Cancer Center
Beverly Canin, Patient Advocate; Cancer and Aging Research Group
Eric H. Rubin, M.D. | Merck Research Laboratories
Heidi Klepin, M.D., M.S.; Wake Forest University
Mihaela Popa McKiver | M.D., Ph.D.; Bristo-Myers Squibb

05:45 PM | Welcome Reception
Thursday May 4, 2017
08:00 AM

Plenary Session II

  • Histology-Agnostic Drug Development: Biologic Rationale, Opportunities, Challenges and Industry Perspective
    Moderators : 
    • Patricia LoRusso, D.O.; Yale University
    • Gregory Reaman, M.D.; U.S. Food and Drug Administration
  • Biologic Insights to Tissue-Agnostic Development of Immune-Oncology Drugs
    Speaker : 
    • Eric H. Rubin, M.D.; Merck Research Laboratories
  • Pre-Clinical Rationale and Strategies for Tissue-Agnostic Drug Development
    Speaker : 
    • Priti Hegde, Ph.D.; Genentech/Roche
  • Industry Perspective on Opportunities and Challenges to Histology-Agnostic Development Programs
    Speaker : 
    • Josh Bilenker, M.D.; Loxo Oncology
  • Panel Discussion
10:00 AM

Break

10:30 AM

Regulatory Sciences II (learners choose one)

  • Biomarker Assay Validation and Companion Diagnostics Requirements for Tissue-Agnostic Drug Development
    Moderator : 
    • Reena Philip, Ph.D.; U.S. Food and Drug Administration

    Panelists : 

    • Ignacio Wistuba, M.D.; MD Anderson Cancer Center
    • Girish Putcha, M.D., Ph.D.; Palmetto GBA MoIDX
  • Regulatory Challenges with Histology-Agnostic Drug Development 
    Moderator : 
    • Rajeshwari Sridhara, Ph.D.; U.S. Food and Drug Administration

    Panelists : 

    • David Hyman, M.D.; Memorial Sloan Kettering Cancer Center
    • Francis J. Giles, M.D.; Northwestern University
    • Richard Pazdur, M.D.; U.S. Food and Drug Administration
    • Mary Redman, Ph.D.; Fred Hutchinson Cancer Research Center
12:30 PM

Lunch

01:30 PM

Case Studies I (learners choose one)

  • Tecentriq® (atezolizumab), Genentech, Inc.
  • Lartruvo™ (olaratumab), Eli Lilly and Company
  • Venclexta™ (venetoclax), Abbvie, Inc.
03:30 PM

Break

04:00 PM

In-Depth Disscussion Groups II (learners choose one)

  • Optimizing the Patient Experience in Cancer Drug Development: Stakeholder Perspectives
    Moderator : 
    • Lola Fashoyin-Aje, M.D., M.P.H.; U.S. Food and Drug Administration

    Panelists : 

    • Rajeshwari Sridhara, Ph.D.; U.S. Food and Drug Administration
    • Patricia Spears, Patient Advocate; Susan G. Komen
    • Sonya L. Eremenco, M.A.; Critical Path Institute
    • Danielle Leach, M.P.A.; St. Baldrick’s Foundation
    • Selena Daniels, Pharm.D., M.S.; U.S. Food and Drug Administration
    • Oliver Rosen, M.D.; Deciphera Pharmaceuticals
    • Michael Carducci, M.D.; Johns Hopkins University
  • Modernizing Eligibility Criteria
    Moderator : 
    • Gwynn Ison, M.D.; U.S. Food and Drug Administration

    Panelists : 

    • Edward Kim, M.D.; Levine Cancer Institute
    • Thomas Uldrick, M.D., M.S.; National Cancer Institute
    • Nancy Lin, M.D.; Dana Farber Cancer Institute
    • Joohee Sul, M.D.; U.S. Food and Drug Administration
    • Nam Atiqur Rahman, Ph.D.; U.S. Food and Drug Administration
  • Global Drug Development: Regulatory and Scientific Issues with Foreign Data
    Moderator : 
    • Renzo Canetta, M.D.; Independent Consultant

    Panelists : 

    • Janet Wittes, Ph.D.; Statistics Collaborative
    • Patricia Keegan, M.D.; U.S. Food and Drug Administration
    • Edward Trimble, M.D., M.P.H.; National Cancer Institute
    • Philip Johnson, M.D., F.R.C.P.; University of Liverpool
  • Real World Evidence and Pragmatic Clinical Trials: Introduction by Sean Khozin, M.D., U.S. Food and Drug Administration
    Moderators : 
    • Sean Khozin, M.D., M.P.H.; U.S. Food and Drug Administration
    • Howard Fingert, M.D.; Takeda Oncology

    Panelists : 

    • Robert S. Miller, M.D., FACP, FASCO; CancerLinQ at American Society of Clinical Oncology
    • Amy Abernethy, M.D., Ph.D.; Flatiron Health
    • Jan Liphardt, Ph.D.; Stanford University
06:00 PM

Networking Reception

Friday May 5, 2017
08:00 AM

Plenary Session III

  • New Developments in Cancer Immunotherapy: Generating Prolonged Anti-Cancer Immunity
    Moderators : 
    • Ke Liu, M.D., Ph.D.; U.S. Food and Drug Administration
    • Jeffrey Weber, M.D., Ph.D.; New York University Langone Medical Center
  • Improving Adaptive Cell Therapy (ACT) for Cancer
    Speaker : 
    • Steven Rosenberg, M.D., Ph.D.; National Cancer Institute
  • Designing New CARs for Cancer Treatment
    Speaker : 
    • Marcela Maus, M.D., Ph.D.; Massachusetts General Hospital
  • Beyond Checkpoint Inhibitors: New Approaches to Altering the Tumor Environment
    Speaker : 
    • Roy S. Herbst, M.D., Ph.D.; Yale Cancer Center, Yale School of Medicine
  • Panel Discussion
10:00 AM

Break

10:30 AM

Regulatory Sciences III (learners choose one)

  • Immunotherapy Endpoints
    Moderator : 
    • Marc Theoret, M.D.; U.S. Food and Drug Administration
  • Evolving Combination Therapies on an Immuno-Oncology Backbone; Regulatory Issues and Pathways
    Panelists : 
    • Jeffrey Weber, M.D., Ph.D.; New York University Langone Medical Center
    • Ke Liu, M.D., Ph.D.; U.S. Food and Drug Administration
12:30 PM

Box Lunches

01:00 PM

Case Studies II (learners choose one)

  • Tecentriq® (atezolizumab), Genentech, Inc.
  • Lartruvo™ (olaratumab), Eli Lilly and Company
  • Venclexta™ (venetoclax), Abbvie, Inc.
03:00 PM

Adjourn

Categories: 2017 AAADV Workshop

Recent Posts
  • Satellite Symposium 2019 Defining the Cancer Care Ecosystem to Determine Value
  • 2019 AAADV WORKSHOP SCHEDULE & AGENDA
  • Event Media Board
  • A Message from the Co-Chairs of the FDA-Duke Global Regulatory Workshop
  • Schedule for FDA-Duke Global Pre-Workshop
Categories
Recent Comments
    Twitter Feed
    Tweets by AAADVWorkshop
    • Event Info
    • Get Whova App
    • Contact Us
    • Sponsors
    • Privacy Policy
    • Twitter
    • Facebook
    • Youtube
    • info@aaadv.org
    Managed by VSolvit.com